The original paper, published online on 19 June 2014, examined whether statins could enhance the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP and Hsp90α. Its title described the proposed interaction in human colorectal cancer, but the retraction means the article’s reported results should not be treated as reliable evidence. The notice does not provide new experimental findings, a replication study or a corrected analysis of the drug combination.

The publisher’s decision was based on the reported overlap in Figures 3B and 3C and the authors’ lack of response to correspondence. The notice specifically says that J Lee and W K Kang did not reply to the publisher’s messages, while the publisher was unable to contact S J Lee, I Lee and C Park. No response from the authors is included in the supplied retraction information.

This is a formal retraction, not a statement that the underlying biological hypothesis has been disproved. The notice identifies concerns about the reliability of the data and withdraws confidence in the article’s reported findings; it does not establish whether further research could test the proposed effects of statins and bevacizumab in colorectal cancer. Any assessment of the combination therefore requires independently verified evidence rather than relying on the retracted publication.

Subject of Research: Retraction of a colorectal cancer study examining statins and bevacizumab

Article Title: Retraction Note: Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer

Article References: Lee, S. J., Lee, I., Lee, J., Park, C., & Kang, W. K. (2026). Retraction Note: Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer. British Journal of Cancer. https://doi.org/10.1038/s41416-026-03656-y

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03656-y

Keywords: retraction, colorectal cancer, statins, bevacizumab, anti-angiogenesis, data reliability, figure overlap, British Journal of Cancer, Note, hydroxy-3-methylglutaryl, coenzyme, reductase

The man was referred to the hospital with multiple pulmonary nodules. His smoking history amounted to approximately 10 cigarettes per day for about 10 years during his twenties and thirties. Histopathological examination showed papillary and lepidic proliferation of mucin-producing tumor cells. At higher magnification, the tumor contained mucin-producing columnar cells with abundant intracellular mucin, consistent with invasive mucinous adenocarcinoma. The disease was staged as cT4N1M1b, or stage IVA. Molecular testing detected no actionable driver alterations, while programmed death-ligand 1 expression was measured at 15%. For a metastasis in the fourth thoracic vertebra, the patient received palliative radiotherapy at a dose of 35 Gy in five fractions.

Systemic treatment with atezolizumab, bevacizumab, carboplatin and paclitaxel was then initiated. On follow-up CT after two cycles, the solid components of the pulmonary tumors had regressed, but their cavitary components had enlarged. The overall dimensions of the lesions therefore increased even though the visible solid material had decreased. The investigators could not determine whether the tumors had progressed from the images alone, so another CT was obtained after two additional treatment cycles. That examination showed no significant changes in the lung fields, but the metastasis in the fourth thoracic vertebra had progressed. The overall disease was consequently judged to be progressive, and the systemic regimen was changed to docetaxel plus ramucirumab.

After three cycles of docetaxel plus ramucirumab, CT showed further enlargement of multiple cavitary lesions. At the same time, their walls became progressively thinner and the residual solid components appeared to regress. The findings were discordant in appearance: enlargement of the cavities could be interpreted as growth, whereas wall thinning and regression of the solid components were compatible with a treatment effect. The investigators concluded that these observations raised the possibility of treatment benefit but did not provide enough objective evidence to determine the overall pulmonary response. One additional chemotherapy cycle was administered, after which treatment was discontinued because the patient’s activities of daily living declined. He received no further chemotherapy and died approximately four months after the final cycle.

Cavitary lesions are commonly observed in squamous cell carcinoma but are relatively uncommon in adenocarcinoma. Cavitary change may also occur as a treatment-related radiological finding. The case report identifies several proposed mechanisms: central tumor necrosis, ischemia, communication with the bronchial tree, a treatment-related reduction in viable tumor cells, and changes in tumor blood flow induced by antiangiogenic agents. In this patient, marked cavitary transformation appeared during treatment with atezolizumab, bevacizumab, carboplatin and paclitaxel and progressed further during docetaxel plus ramucirumab. The investigators considered antiangiogenic therapy a possible contributor, while stating that the precise mechanism remained uncertain.

Inhibition of the vascular endothelial growth factor pathway may cause vascular regression, intratumoral ischemia and necrosis, processes that have been proposed to promote cavitary transformation during antiangiogenic treatment of non-small-cell lung cancer. The treatment sequence and imaging pattern in this case were temporally compatible with such a contribution because marked cavitation developed during the regimen containing bevacizumab and continued during a subsequent regimen containing ramucirumab. Nevertheless, the case cannot separate the effects of the two antiangiogenic agents from those of chemotherapy or immunotherapy, and it does not establish that either drug caused the imaging changes. It also cannot determine whether all enlarging cavities represented the same biological process.

The timing of cavitary transformation could not be established with certainty. A limited-field CT scan obtained two days before the first systemic regimen showed no cavitary changes in the portion of the lung included. That examination was performed primarily to evaluate the fourth thoracic vertebral metastasis and did not cover the entire lungs, so interval changes in lesions outside the imaged field could not be completely excluded. The absence of visible cavitation on the limited scan therefore did not definitively establish when it began. The later imaging nevertheless documented a clear sequence of enlarging cavities, thinning cavity walls and regressing residual solid components, producing the central radiological dilemma in this case.

Response assessment for solid malignancies commonly uses the Response Evaluation Criteria in Solid Tumors, or RECIST. The authors describe RECIST as a practical and useful standard for most patients, but the case demonstrates the difficulty posed by pronounced cavitary transformation. In this setting, an increase in external lesion diameter may suggest progression even when the residual solid component is regressing and the cavity wall is thinning. Overall diameter describes the lesion’s footprint, whereas the solid component and wall thickness describe features of its internal composition. When these measurements change in opposite directions, assessment based only on external size may become uncertain or potentially misleading.

Serum carcinoembryonic antigen, or CEA, and SLX levels did not resolve the uncertainty. Both remained within their normal ranges throughout treatment and therefore did not provide useful information for monitoring the response. The investigators concluded that marked, multifocal cavitary transformation can produce discordant morphological changes that complicate radiological evaluation. They state that assessment in such cases should incorporate cavity-wall thickness, residual solid components, overall tumor distribution and the clinical course rather than relying solely on external lesion diameter. These observations remain limited to one patient and cannot establish the frequency of the pattern, identify its biological cause or show that any particular regimen improved survival.

The case ultimately also demonstrates the limits of assigning a response when imaging, blood markers and the course at another metastatic site do not converge. Lung imaging suggested a possible treatment effect in the composition of the lesions, while progression in the fourth thoracic vertebra supported classifying the overall disease as progressive. No further systemic therapy followed, and the patient died roughly four months after the final chemotherapy cycle; those events do not establish what the pulmonary lesions represented or whether continued treatment would have changed the outcome. The report’s principal value is therefore focused and descriptive: it documents an uncommon imaging scenario in which enlarging cavities, thinning walls and regressing solid components coexist, making conventional size-based response assessment difficult and leaving clinicians to act amid persistent uncertainty.

Subject of Research: Treatment-related cavitary transformation complicating response assessment in invasive mucinous lung adenocarcinoma

Article Title: Discordant Cavitary Changes: A Radiological Dilemma in Invasive Mucinous Adenocarcinoma: A Case Report

Article References: Nigi, A., Miya, N., Iwamoto, K., Itani, H., & Kondou, S. (2026). Discordant Cavitary Changes: A Radiological Dilemma in Invasive Mucinous Adenocarcinoma: A Case Report. Respirology Case Reports, 14(10), Article e70791. https://doi.org/10.1002/rcr2.70791

Image Credits: AI Generated

DOI: 10.1002/rcr2.70791

Keywords: invasive mucinous adenocarcinoma, lung cancer, tumor cavitation, computed tomography, RECIST, antiangiogenic therapy, radiological response assessment, case report, bevacizumab, ramucirumab, Discordant, Cavitary

Patients with clear cell carcinoma were younger than those with high-grade serous carcinoma, with reported ages of 51 versus 58 years, and they had lower CA-125 levels. They also received frontline PARP inhibitors less frequently: 4.8% compared with 24% among patients with high-grade serous disease, a difference with a p value of 0.007. The objective response rate was numerically higher among bevacizumab recipients than among patients who did not receive the drug, at 90% versus 78%, but this comparison did not meet the conventional statistical threshold (p = 0.078).

Bevacizumab use was also associated with a different recurrence pattern. The abstract reported disseminated peritoneal recurrence in 31% of bevacizumab recipients versus 49% without bevacizumab, while pelvic or focal recurrence occurred in 15% and 2.2%, respectively; the overall comparison between recurrence patterns had a p value of 0.025. Kaplan–Meier analyses found significantly better overall survival (p = 0.0012) and progression-free survival (p = 0.01) with bevacizumab across the full cohort. The overall-survival association was particularly pronounced in the high-grade serous subgroup (p = 0.0061).

In multivariable analysis, clear cell histology independently predicted worse overall survival, with a hazard ratio of 3.03 (95% confidence interval, 1.71–5.34; p < 0.001), and worse progression-free survival, with a hazard ratio of 1.81 (95% CI, 1.10–3.00; p = 0.02). Frontline bevacizumab was independently associated with longer overall survival, with a hazard ratio of 0.52 (95% CI, 0.30–0.90; p = 0.019). The survival association in the clear cell subgroup did not reach statistical significance, although its direction was consistent with that in high-grade serous carcinoma, and no significant interaction by histology was detected (p = 0.505). The authors noted that the retrospective design and limited subgroup sizes require validation in prospective studies; the supplied evidence is an abstract from an early-access version subject to further edits, not a full assessment of the article.

Subject of Research: Associations between frontline bevacizumab, survival, and recurrence patterns in advanced ovarian cancer by histology

Article Title: Frontline bevacizumab in ovarian clear cell versus high-grade serous ovarian cancer: survival outcomes and recurrence patterns in a real-world cohort

Article References: Gao, Y.-T., Chang, C. Y.-Y., Chang, W.-C., Hung, Y.-C., Lin, W.-C., Sung, Y.-W., & Yeh, L.-S. (2026). Frontline bevacizumab in ovarian clear cell versus high-grade serous ovarian cancer: survival outcomes and recurrence patterns in a real-world cohort. BMC Cancer. https://doi.org/10.1186/s12885-026-17030-x

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17030-x

Keywords: ovarian cancer, bevacizumab, clear cell carcinoma, high-grade serous carcinoma, overall survival, progression-free survival, recurrence patterns, retrospective cohort, observational study, Frontline, ovarian, clear

The research team, led by investigators at Beijing University of Chinese Medicine and Peking University Third Hospital, systematically searched PubMed, Embase, and the Cochrane Library through 6 November 2025. From an initial haul of 1,180 records, they identified ten randomized controlled trials encompassing 3,959 patients with metastatic colorectal cancer who had progressed after second-line therapy. Each trial compared one of the three oral agents—alone or, in some cases, TAS-102 combined with bevacizumab—against placebo or best supportive care. Risk of bias was assessed with the Cochrane RoB-2 tool, and the protocol was prospectively registered with PROSPERO.

Because no trial has ever randomized patients directly between regorafenib, fruquintinib, and TAS-102, the researchers turned to network meta-analysis, a statistical framework that uses a common comparator—in this case placebo—to make indirect comparisons across trials. They fitted a Bayesian random-effects consistency model with non-informative normal priors, ran four parallel Markov chains through 20,000 adaptation iterations and 50,000 sampling iterations, and confirmed convergence using the Gelman-Rubin diagnostic. The resulting network was star-shaped, anchored on placebo, with no closed loops among the active treatments, which meant formal inconsistency testing was impossible; instead, the team relied on transitivity checks comparing trial characteristics and potential effect modifiers.

The headline finding for the overall population was straightforward: every active treatment significantly prolonged overall survival compared with placebo. Fruquintinib produced a hazard ratio of 0.66 (95% credible interval 0.53–0.84), regorafenib 0.69 (0.51–0.88), TAS-102 0.69 (0.55–0.85), and TAS-102 plus bevacizumab 0.41 (0.28–0.59). The combination of TAS-102 with bevacizumab ranked first by SUCRA—the surface under the cumulative ranking curve—while the three single agents showed broadly similar efficacy, with indirect differences among them not consistently statistically significant. Progression-free survival followed the same pattern, with all experimental arms outperforming placebo and the doublet again delivering the largest benefit.

One indirect comparison did stand out: fruquintinib showed a more favorable progression-free survival than TAS-102, with a hazard ratio of 0.65 (95% CrI 0.45–0.96), placing it highest among the monotherapies. The authors caution, however, that this estimate rests entirely on indirect evidence in the absence of head-to-head trials and should be interpreted cautiously. Heterogeneity also varied considerably across the network: it was essentially absent for fruquintinib versus placebo (I² ≈ 0%), moderate for TAS-102 (OS I² = 21.8%), and high for regorafenib (OS I² = 67.5%, PFS I² = 83.1%), prompting the use of random-effects models throughout.

The most novel contribution of the analysis lies in its KRAS stratification. During transitivity checks, KRAS mutational status emerged as the most plausible source of the between-study heterogeneity, driven largely by differences in baseline KRAS prevalence—Asian trials such as CONCUR and TERRA enrolled 34% and 37% KRAS-mutant patients respectively, while the remaining trials ranged from 40% to 70%. When the team restricted the analysis to trials reporting KRAS-subgroup overall survival data, heterogeneity collapsed dramatically in the wild-type subgroup, with I² falling to 20% or below for every comparison, and the three agents ranked almost side by side with no meaningful differences between them.

In the KRAS-mutant subgroup, the picture shifted subtly. Fruquintinib and TAS-102 each produced numerically favorable overall survival estimates versus placebo—hazard ratios of 0.71 (95% CrI 0.51–1.01) and 0.74 (95% CrI 0.50–0.99) respectively—whereas regorafenib did not reach statistical significance, with a hazard ratio of 0.81 (95% CrI 0.52–1.19). The exploratory ranking placed fruquintinib first, TAS-102 second, and regorafenib last. The authors are emphatic, however, that these differences in statistical significance versus placebo do not demonstrate superiority of fruquintinib or TAS-102 over regorafenib, and that the rank probabilities are hypothesis-generating rather than evidence of a predictive effect of KRAS status.

The mechanistic backdrop helps explain why KRAS status might matter. KRAS is mutated in approximately 40% of colorectal cancers, driving constitutive RAS signaling and unrestrained cell growth. Prior laboratory work has suggested that exon-2 KRAS mutations, particularly G12C and G12A, maintain elevated BRAF-ERK-ELK phosphorylation and blunt regorafenib-induced apoptosis and vessel shutdown, while a recently described KRAS/ERK2–TRIM21–c-Myc/ENO2 glycolytic axis promotes regorafenib resistance. Notably, among the three TAS-102 trials, the Japanese phase 2 study by Yoshino and colleagues showed a markedly stronger benefit in KRAS-mutant patients (hazard ratio 0.44) than in wild-type disease (0.70), a pattern that largely accounts for the residual heterogeneity in that treatment node.

The combination of TAS-102 with bevacizumab emerged as the standout regimen overall. Mechanistically, the pairing is plausible: trifluridine inhibits thymidylate synthase and, through its metabolite FTY, becomes incorporated into DNA causing miscoding, while tipiracil protects trifluridine from degradation by blocking thymidine phosphorylase; bevacizumab, meanwhile, suppresses VEGF-driven angiogenesis and remodels the tumor microenvironment. The authors suggest these mechanisms may act synergistically, and a separate analysis indicated the combination conferred a particularly pronounced survival benefit in RAS-mutant patients (hazard ratio 0.38, 95% CrI 0.19–0.79) with no significant advantage over monotherapy in the wild-type population—though only one study contributed to that subgroup node, precluding a stable network estimate.

The study has clear limitations that the authors acknowledge candidly. No head-to-head randomized comparisons exist among the three agents, the star-shaped network precluded formal inconsistency testing, and individual-participant data were unavailable, so a formal treatment-by-KRAS interaction test could not be performed. Comparative safety was not formally meta-analyzed because safety definitions and reporting thresholds differed substantially across trials, and progression-free survival subgroup analysis was abandoned due to insufficient sample size and high heterogeneity (I² ranging from 77.7% to 92.2%). Publication-bias testing was deemed unreliable with fewer than ten trials per outcome. The authors conclude that for KRAS-wild-type patients, standard third-line regimens or TAS-102 plus bevacizumab are reasonable, while for KRAS-mutant patients fruquintinib may represent a sensible later-line option—pending confirmation from prospective, KRAS-stratified or head-to-head trials that the field has yet to deliver.

Subject of Research: Comparative efficacy of third-line oral therapies for KRAS-mutant metastatic colorectal cancer

Article Title: Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis

Article References: Zhou, Y., Zhao, S., Zheng, X., Wang, Y., Wang, M., Chen, S., Wu, Z., Zang, D., & Si, W. (2026). Comparative efficacy of fruquintinib, regorafenib or TAS-102 in patients with KRAS-mutant metastatic colorectal cancer: a systematic review and network meta-analysis. Frontiers in Oncology, 16, Article 1948508. https://doi.org/10.3389/fonc.2026.1948508

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1948508

Keywords: fruquintinib, regorafenib, TAS-102, KRAS mutation, metastatic colorectal cancer, network meta-analysis, overall survival, progression-free survival, bevacizumab, third-line therapy, precision oncology, Bayesian analysis

To understand why the study matters, it helps to understand what biosimilars are and how they differ from the generic drugs most consumers know. Conventional small-molecule medications can be copied exactly, and their generics must demonstrate bioequivalence through relatively straightforward testing. Biologic drugs, by contrast, are large, complex molecules manufactured inside living cells, which makes them inherently variable and impossible to replicate precisely. Biosimilars are therefore defined as products that are highly similar to an originator biologic, with no clinically meaningful differences in safety, purity or potency. A federal policy enacted in 2009 established an abbreviated regulatory pathway designed to bring these products to the U.S. market, with the explicit goals of increasing competition, lowering prices and improving access to biologic treatments. By the end of 2024, thirteen biosimilars had been approved for three of the most widely used cancer biologics: bevacizumab, rituximab and trastuzumab, drugs deployed against breast cancer, lymphoma, colorectal cancer, lung cancer and ovarian cancer.

The financial stakes in oncology could hardly be higher. Previous research has estimated that financial toxicity, the measurable hardship caused by the cost of care, may affect as many as half of all patients with cancer in the United States. That hardship is not merely a matter of household budgets; it has been linked to medication nonadherence and poorer health outcomes, meaning that high drug prices can directly undermine the effectiveness of treatment. Biologic drugs are a major contributor to this burden because of their complexity and cost. While earlier studies had shown that biosimilar competition in other therapeutic areas can drive down prices and shift prescribing toward cheaper alternatives, far less was known about what happened across these three major cancer drugs after biosimilar entry, and crucially, whether any market changes actually translated into lower costs for insurers and patients in everyday cancer care.

To close that gap, the UCLA team conducted a retrospective cohort study built on health insurance claims data. They identified 14,655 patient-drug pairs involving people with cancer who initiated treatment with bevacizumab, rituximab or trastuzumab between 2020 and 2023, a period that spans the market entry of biosimilars for all three drugs. The cohort included patients with commercial insurance as well as those with Medicare-related coverage, and the researchers tracked each patient’s treatment and costs for twelve months after the start of biologic therapy. Patients were sorted into four groups: those who exclusively used a biosimilar, those who exclusively used the originator product, those who switched from the originator to a biosimilar, and those who switched from a biosimilar back to the originator. Monthly insurer payments and patient out-of-pocket costs, calculated as the sum of deductibles, copayments and coinsurance, were compared across the groups after adjusting for differences in patient characteristics and treatment patterns.

The adoption patterns the researchers observed were striking. Among the patient-drug pairs, 59.4 percent of patients exclusively used a biosimilar during the first twelve months of treatment, while 32.5 percent exclusively used the originator. Only 6.9 percent switched from the originator to a biosimilar, and a mere 1.2 percent moved in the opposite direction. In other words, biosimilars captured the market primarily at the point of treatment initiation rather than through conversion of patients who were already mid-course on the branded drugs. That distinction carries practical weight: it suggests that the moment a clinician and patient choose which biologic to start may be the single most important leverage point for expanding the use of lower-cost alternatives, since switching established patients appears to be relatively rare.

The cost differences between the groups were substantial. After adjustment, average monthly payer costs were $8,959 for patients who exclusively used biosimilars, compared with $12,779 for those who exclusively used the originator, a gap of $3,820 every month of treatment. Out-of-pocket savings were smaller in absolute terms but still meaningful: patients on biosimilars paid an average of $118.90 per month versus $158.40 for those on originators, a difference of $39.50 per month. Senior author Tina Shih, director of the Cancer Health Economics Research Program at the UCLA Health Jonsson Comprehensive Cancer Center and professor of Health Economics in the Department of Radiation Oncology, acknowledged the asymmetry but emphasized its human significance. Although the savings were substantially greater for insurers than for patients, she noted, even modest reductions in out-of-pocket costs may be meaningful for people facing the financial challenges of cancer care, since those savings can be directed toward other treatment-related expenses or everyday living costs.

Beyond the patient-level comparisons, the study documented clear market-wide effects of biosimilar entry. The average sales price of the three originator biologics declined by 3.8 percent per year after biosimilars entered the market, evidence that competition pressured the branded products themselves rather than simply carving off a slice of demand. Meanwhile, the originators’ market share fell by roughly 30 percent annually among patients with commercial insurance and 31.5 percent within Medicare Part B. The biosimilars themselves were also becoming cheaper over time: the average sales price of the twelve biosimilar products included in the study declined by 12.4 percent per year, a pattern consistent with intensifying price competition among multiple manufacturers of similar products. Together, these trends indicate that the biosimilar pathway is functioning as intended, reshaping prices across the entire category rather than at the margins.

First author Xiaoyu Liu, a former PhD student in the Department of Health Policy and Management at the UCLA Fielding School of Public Health, framed the findings as timely support for ongoing regulatory efforts. The FDA has continued to take regulatory actions aimed at further unlocking biosimilar competition, Liu said, and the study’s results offer further evidence to support patients, providers and insurers in their consideration of biosimilars. The research team also included Xiaoyi Xu and Z. JohnLu of UCLA. Because the analysis relied on insurance claims rather than clinical records, it speaks primarily to utilization and cost rather than to treatment outcomes, but the regulatory standard for biosimilars, no clinically meaningful differences from the originator, underpins the assumption that the cheaper products deliver equivalent care. The study’s retrospective design also means the associations reflect real-world prescribing behavior rather than a controlled experiment, which is precisely what makes them valuable for policy discussions.

Taken together, the findings sketch a healthcare market in transition. Biosimilars now account for the majority of new treatment starts across three of oncology’s most important biologics, their prices are falling year over year, and their presence is pulling down the prices of the branded originals as well. For the health system, the monthly savings of nearly $4,000 per patient on payer costs represent the kind of aggregate figure that could reshape oncology budgets if adoption continues to climb. For individual patients, the roughly $40 in monthly out-of-pocket relief is modest against the backdrop of cancer’s total financial toll, yet it arrives at a time when financial toxicity affects up to half of American cancer patients and contributes to treatment abandonment and worse outcomes. The study also highlights a practical prescription: because biosimilar uptake happens overwhelmingly at treatment initiation, clinicians, insurers and policymakers who want to widen access to these equally efficacious, lower-cost alternatives should focus their efforts on the first prescription, where the choice between originator and biosimilar is actually made.

Subject of Research: Economic impact of biosimilar competition on cancer biologic drug costs for insurers and patients

Article Title: Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds

Article References: Cancer biosimilars associated with lower costs for insurers and patients, UCLA study finds. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: biosimilars, cancer biologics, bevacizumab, rituximab, trastuzumab, drug pricing, financial toxicity, JAMA Oncology, UCLA, health economics, Medicare Part B, FDA regulation

Radiation necrosis is one of the most feared late complications of cranial radiotherapy. The condition arises when radiation injures the small blood vessels of the brain, triggering a cascade of hypoxia, inflammation, and abnormal VEGF signaling that makes the blood-brain barrier permeable. Fluid accumulates in the surrounding tissue, producing cerebral edema that can cause headaches, seizures, cognitive decline, and progressive neurological deterioration. Historically, clinicians managed the condition with corticosteroids, but long-term steroid exposure carries its own heavy burden of side effects, including immunosuppression, myopathy, diabetes, and osteoporosis. Bevacizumab offered a mechanistically elegant alternative: by neutralizing VEGF, it directly targets the vascular pathology driving the edema, and multiple studies since a landmark randomized placebo-controlled trial in 2011 have confirmed its radiographic and clinical efficacy.

What has remained unclear is whether the doses borrowed from oncology practice, where the drug is used against glioblastoma and metastatic disease, are actually necessary for a non-neoplastic condition like radiation necrosis. Standard regimens typically range from 7.5 to 10 milligrams per kilogram of body weight administered every three weeks, but head-to-head comparisons of these dosing strategies have been lacking. The new study, led by Sydney E. Schultz of the Department of Pharmacy at Mayo Clinic in Rochester, Minnesota, together with collaborators across multiple institutions, set out to fill that gap with a comparative analysis of real-world patients treated between June 2021 and July 2024.

The research team assembled a cohort of 104 adults who had received bevacizumab for radiation necrosis after treatment for either primary central nervous system tumors or brain metastases. Fifty-three patients received the lower dose of 7.5 milligrams per kilogram every three weeks, while 51 received the higher dose of 10 milligrams per kilogram on the same schedule. The primary outcome was edema response, assessed by a neuro-oncologist who was blinded to the dose each patient had received, a design feature intended to minimize assessment bias. Secondary outcomes included response of contrast-enhancing disease on imaging, clinical response, adverse events, treatment discontinuation, and the need for re-dosing when radiation necrosis recurred.

The results delivered an instructive lesson in the pitfalls of observational research. In unadjusted analyses, edema response appeared to differ significantly between the two dosing groups, with the lower-dose cohort actually faring better, a counterintuitive finding that might have prompted headlines proclaiming that less is more. But the two groups were not comparable at baseline: tumor type differed markedly between them, with significantly more patients harboring primary central nervous system tumors in the 10 milligrams per kilogram group. When the researchers adjusted their analysis for tumor type, the apparent advantage of the lower dose attenuated, suggesting that the underlying biology of the original tumor, rather than the dose of the antibody, was driving the difference in edema outcomes.

Contrast-enhancing disease response, a separate radiographic measure tracking the abnormal enhancement visible on magnetic resonance imaging, showed no difference between the dosing groups in either unadjusted or adjusted analyses. Clinical response, however, told a different story: 65.2 percent of patients in the lower-dose group experienced clinical improvement compared with 37.8 percent in the higher-dose group, a statistically significant difference. The authors note that this finding, like the edema result, must be interpreted cautiously given the confounding by tumor type and the retrospective design, but it raises the possibility that higher doses do not translate into better patient-centered outcomes.

Equally important were the safety findings. Rates of adverse events, treatment discontinuation, and re-dosing for recurrent radiation necrosis were similar between the two dosing groups. This is a meaningful observation because bevacizumab is not a benign medication. Its inhibition of VEGF impairs normal vascular repair and has been associated with hypertension, impaired wound healing, and, concerningly, dose-dependent risk of intracranial hemorrhage in patients with malignant gliomas, as documented in prior work by some of the same research group. If lower dosing achieves comparable radiographic outcomes, the potential to reduce exposure-related toxicity becomes a compelling argument for careful dose selection.

The study’s central conclusion is that both 7.5 and 10 milligrams per kilogram dosing strategies achieved similar radiographic outcomes, and that these findings support an individualized approach to bevacizumab dosing in radiation necrosis. The authors emphasize that prospective, tumor-stratified studies incorporating edema-focused and patient-centered endpoints are needed to define optimal dosing strategies in this heterogeneous population. The call is significant in context: a recent European Association for Neuro-Oncology consensus statement on radiation necrosis underscores how much clinical practice in this field still rests on retrospective series and expert opinion rather than randomized evidence. Meanwhile, parallel research efforts, including phase II trials of single low-dose bevacizumab infusions and studies of low-dose regimens in nasopharyngeal carcinoma survivors, reflect a growing international interest in de-escalating bevacizumab exposure without sacrificing efficacy.

For patients and clinicians, the study’s message is one of cautious reassurance and practical flexibility. Radiation necrosis is not a single disease but a vascular syndrome that arises in different biological contexts, whether after treatment of a glioma, a meningioma, a vestibular schwannoma, or metastatic deposits from lung or breast cancer, and the edema it produces may respond differently depending on that context. The Mayo Clinic-led analysis suggests that clinicians need not reflexively default to the higher oncology-derived dose, and that tumor type should inform both dosing decisions and the interpretation of treatment response. Until prospective, tumor-stratified trials deliver definitive answers, the findings argue for tailoring bevacizumab therapy to the individual patient, weighing radiographic response against clinical benefit, toxicity risk, and the biological terrain left behind by the original tumor and its treatment.

Subject of Research: Comparative bevacizumab dosing for cerebral radiation necrosis and the influence of tumor type on edema response

Article Title: Comparative dosing of bevacizumab for radiation necrosis: impact of tumor type on edema response

Article References: Schultz, S. E., Labib, M., Breit, J., Barreto, J. N., Mead-Harvey, C., Behair, M., Nurioglu, A., White, J., Valerius, A., Karbhari, N., Taraba, J., Soefje, S., Hoefs, G., Caron, S. J., Ruff, M. W., Uhm, J. H., Lachance, D. H., Kizilbash, S. H., Campian, J. L., … Sener, U. (2026). Comparative dosing of bevacizumab for radiation necrosis: impact of tumor type on edema response. Journal of Neuro-Oncology, 180(1), Article 12. https://doi.org/10.1007/s11060-026-05826-7

Image Credits: AI Generated

DOI: 10.1007/s11060-026-05826-7

Keywords: bevacizumab, radiation necrosis, cerebral edema, VEGF, brain tumors, brain metastases, dosing, neuro-oncology, blood-brain barrier, Mayo Clinic, retrospective cohort study, drug safety

Bevacizumab is a monoclonal antibody that blocks vascular endothelial growth factor, or VEGF, a signalling protein that drives the growth of the abnormal, leaky blood vessels that destroy central vision in wet age-related macular degeneration. Although the drug was originally developed and approved as an intravenous cancer therapy, ophthalmologists have used it off-label inside the eye for nearly two decades because it is inexpensive and effective. When injected directly into the vitreous cavity, the dose is tiny, typically 1.25 milligrams in 0.05 millilitres, and the conventional assumption has been that systemic exposure is negligible. Yet pharmacokinetic studies suggest that intravitreal bevacizumab may produce higher blood levels than some other anti-VEGF agents, and the full systemic consequences of repeated exposure in elderly, medically complex patients remain incompletely mapped.

The patient in this report had already received two bevacizumab injections without any psychiatric symptoms. The third injection, delivered to her right eye, was designated Day 0 by the clinical team. On Day +1, before her scheduled left-eye injection on Day +2, she developed persecutory delusions, heard voices, could not sleep, and expressed suicidal ideation. Her behaviour changed markedly. This abrupt onset, arriving within hours of the procedure, is precisely the kind of temporal pattern that prompts clinicians to look for an external trigger rather than a slowly evolving primary psychiatric illness.

What makes the case compelling is the thoroughness of the exclusion workup. The woman had hypertension, type 2 diabetes, and atrial fibrillation, and she was taking multiple medications, a combination that in geriatric patients frequently hides drug interactions, toxicity, or withdrawal syndromes behind a psychiatric presentation. Careful medication reconciliation revealed no recent changes of any kind. Urine toxicology was negative, ruling out illicit substances. There were no major psychosocial stressors and no family history of psychiatric disease. No corticosteroids, which are sometimes co-administered around eye injections and are well known to provoke psychosis in older adults, were documented peri-injection or topically.

The neurological evaluation was equally revealing. On examination the patient was oriented, her memory was intact, and her Mini-Mental State Examination score was 27 out of 30, essentially normal for her age. The Confusion Assessment Method, a bedside screen for delirium, was negative, arguing against the fluctuating inattention that characterises acute confusional states. Brain magnetic resonance imaging showed only mild age-related atrophy and chronic small-vessel ischaemic changes, with no acute lesions, no diffusion restriction, and no evidence of stroke. Laboratory findings were unremarkable. In other words, the usual structural, metabolic, and toxicological culprits of late-life psychosis were systematically absent, leaving the timing of the injection as the most striking anomaly in the clinical picture.

The treating psychiatrists initiated aripiprazole, a second-generation antipsychotic, at 2.5 milligrams per day and gradually titrated the dose to 7.5 milligrams per day. The psychotic symptoms resolved during treatment, and by Day +33 the patient was discharged in stable condition. She then entered a six-month follow-up period during which she experienced no recurrence, including a subsequent re-exposure to bevacizumab while continuing aripiprazole. That re-challenge is scientifically double-edged. It suggests that the antipsychotic may have protected her against a drug-triggered reaction, but it also weakens the causal argument, because a true drug-induced psychosis would typically be expected to recur on re-exposure unless pharmacologically suppressed.

The authors are careful about this ambiguity, and their caution is warranted. Causal attribution in an elderly patient with vascular comorbidities is notoriously difficult. Cerebral small-vessel disease, which her MRI showed, is itself associated with late-onset psychotic symptoms, and the blood-brain barrier in older hypertensive patients may be more permeable than in younger brains. One plausible biological hypothesis is that systemically circulating bevacizumab, or the downstream reduction in VEGF signalling, could interact with vulnerable cerebral vasculature or with neurovascular regulation in a brain already strained by chronic ischaemia and polypharmacy. VEGF plays roles in vascular integrity and possibly in neuronal support, and interfering with it in a compromised brain is a hypothesis that has never been rigorously tested in this population.

The case also highlights a broader blind spot in drug safety monitoring. Intravitreal anti-VEGF injections are among the most frequent procedures in medicine, delivered in repeated monthly or bimonthly cycles, often for years. Because the treated population is overwhelmingly elderly and carries heavy burdens of cardiovascular disease, diabetes, and concurrent medication, new psychiatric symptoms in these patients are almost reflexively attributed to dementia, delirium, or psychosocial factors. A rare signal, occurring in perhaps one patient among thousands, could easily be swallowed by that background noise. Case reports such as this one function as an early-warning system, prompting pharmacovigilance databases and regulators to look for converging reports that would otherwise go unconnected.

For clinicians, the practical message is not to abandon bevacizumab, which remains a mainstay of retinal care with a strong efficacy and safety record, but to maintain diagnostic vigilance. The authors suggest that when new-onset psychosis emerges in a polymedicated geriatric patient shortly after an intravitreal anti-VEGF injection, a medication-related adverse effect deserves a place on the differential diagnosis, alongside the more familiar neuropsychiatric explanations. Structured medication reconciliation, toxicology screening, neuroimaging, and delirium assessment, all of which were performed in this case, provide the framework for distinguishing a possible drug trigger from multifactorial decompensation.

Whether the association is causal or coincidental cannot be settled by a single patient, and the authors state this plainly. What the case offers instead is a precisely documented temporal sequence, a negative workup for competing causes, a documented treatment response, and a six-month outcome including re-exposure, the raw material from which larger pharmacovigilance studies can build. As the population ages and anti-VEGF therapy expands, the incident reminds medicine that even a needle aimed at the retina can, on rare occasions, reach somewhere far more unexpected.

Subject of Research: Possible psychiatric adverse effects of intravitreal bevacizumab in an elderly patient

Article Title: Possible triggering of psychotic symptoms after repeated intravitreal bevacizumab exposure in a polymedicated geriatric patient: a case report

Article References: Gulec, B. B., Bisgin, E., Akbas, I., & Guclu, O. (2026). Possible triggering of psychotic symptoms after repeated intravitreal bevacizumab exposure in a polymedicated geriatric patient: a case report. BMC Psychiatry. https://doi.org/10.1186/s12888-026-08567-z

Image Credits: AI Generated

DOI: 10.1186/s12888-026-08567-z

Keywords: bevacizumab, intravitreal injection, psychosis, age-related macular degeneration, anti-VEGF therapy, adverse drug reaction, geriatric psychiatry, aripiprazole, case report, pharmacovigilance, delusions, small-vessel disease

The team focused on non-small cell lung cancer (NSCLC), the most common form of lung malignancy, and on bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor A (VEGFA), the master signal that tumors use to recruit new blood vessels. Bevacizumab does suppress neovascularization, but its benefit is frequently transient. The researchers set out to determine what the tumor does in response to this blockade, and the answer they uncovered is a classic example of biological compensation: the very act of cutting off the oxygen supply activates a survival program that helps the tumor adapt and evade the therapy.

Using human NSCLC cell systems, the investigators showed that inhibiting VEGFA paradoxically intensifies intratumoral hypoxia, the oxygen-starved state that develops when vessels fail to keep pace with tumor growth. Hypoxia is not merely a passive consequence of poor blood supply; it is a potent signaling condition. Under low oxygen, the transcription factor HIF1A is stabilized and accumulates in the nucleus, where it switches on a battery of genes that promote malignancy. In their experiments, VEGFA inhibition was consistently accompanied by an upregulation of HIF1A, and elevated HIF1A in turn drove measurable increases in tumor cell migration, epithelial-to-mesenchymal transition (the process by which stationary epithelial cells acquire the motile, invasive traits of mesenchymal cells), and resistance to cisplatin, a mainstay chemotherapy drug for lung cancer.

Perhaps the most consequential discovery concerns CD105, also known as Endoglin. The study found that HIF1A upregulates CD105, a hypoxia-responsive pro-angiogenic mediator expressed on proliferating endothelial cells. In practical terms, this means that when bevacizumab blocks VEGFA and the tumor becomes hypoxic, the resulting HIF1A surge pushes endothelial cells toward CD105-dependent vessel formation, an alternative angiogenic route that the antibody does not touch. The researchers describe this as a hypoxia-driven HIF1A-CD105 axis that sustains tumor aggressiveness and vascular adaptation despite continued VEGFA blockade. It is a molecular account of why anti-angiogenic therapy so often buys time rather than cures: the treatment itself creates the conditions for vascular escape.

Having identified the resistance circuit, the team went looking for a way to disable both of its nodes at once, and they found it in an unexpected place: the precursor of a naturally occurring microRNA. MicroRNAs are short regulatory RNA molecules that fine-tune gene expression by binding complementary sequences in target messenger RNAs and repressing their translation or stability. Most microRNAs are produced from hairpin-shaped precursors, and the canonical model treats one strand of the resulting duplex as the functional guide strand while the other, the passenger strand, is discarded as waste. The pre-miR-16-1 hairpin defies this simplification, and the new study demonstrates that both of its strands carry therapeutic information.

The guide strand, miR-16-5p, directly represses VEGFA, functionally recapitulating the anti-angiogenic action of bevacizumab but at the level of gene expression rather than protein neutralization. The passenger strand, miR-16-1-3p, performs an entirely different and complementary task: it suppresses HIF1A expression itself, preventing the hypoxia-induced malignant program from ever being switched on and, as a downstream consequence, limiting the upregulation of CD105. In other words, a single duplex derived from a physiological microRNA precursor contains, in its two strands, a coordinated attack on both the angiogenic engine and the adaptive hypoxic feedback that ordinarily undermines anti-angiogenic drugs.

The functional analyses underpinning this claim were systematic. When the researchers inhibited VEGFA alone, they observed the expected rise in HIF1A along with the associated malignant phenotypes: enhanced migration, mesenchymal-like morphological changes, and increased cisplatin resistance. When they co-expressed miR-16-1-3p, HIF1A levels fell and these adverse phenotypes were attenuated. This strand-by-strand dissection establishes causality rather than mere correlation: the passenger strand is not a passive byproduct of microRNA biogenesis but an active suppressor of the hypoxic response, and its inclusion is what converts a one-target intervention into a two-target one.

The decisive test came in vivo. Using the chick chorioallantoic membrane (CAM) xenograft model, a widely used platform in which human tumor cells are grafted onto the vascularized membrane of a chick embryo, the team compared single anti-angiogenic intervention with the dual regulatory approach. The results were striking. Dual regulation of VEGFA and HIF1A markedly reduced vascular density, tumor growth, and metastatic dissemination compared with blocking VEGFA alone. The reduction in metastatic burden is particularly noteworthy, because it suggests that suppressing the hypoxic response does more than improve vascular control; it also removes a key driver of the invasive and migratory behavior that allows cancer cells to seed distant sites.

The broader significance of the work lies in its reframing of anti-angiogenic resistance. Rather than treating resistance as an accident of tumor evolution, the study characterizes it as a predictable, pathway-level consequence of therapy: block VEGFA, induce hypoxia, stabilize HIF1A, upregulate CD105, and the tumor rebuilds its blood supply through a route the drug cannot reach. This logic suggests that the therapeutic window for anti-angiogenic treatment in NSCLC could be substantially widened by pairing VEGFA suppression with simultaneous HIF1A inhibition, and the pre-miR-16-1 duplex provides a proof of concept for how that pairing might be achieved with a single physiological molecule.

There are, of course, distance markers between a chick embryo membrane and the clinic. Delivering RNA duplexes reliably to tumor cells in human patients remains a formidable challenge, and the safety profile of simultaneously suppressing HIF1A, a transcription factor with normal roles in physiology, will require careful evaluation. Nevertheless, the study establishes a clear mechanistic framework and a candidate dual-regulatory agent grounded in the cell’s own RNA biology. By showing that the two strands of a single microRNA precursor can cooperate to strike both the VEGF pathway and the hypoxic feedback loop that rescues it, the researchers have turned a discarded passenger strand into a potential therapeutic partner, and they have given the field a concrete strategy for making anti-angiogenic therapy in lung cancer live up, at last, to its original promise.

Subject of Research: Dual targeting of VEGFA and HIF1A pathways by the pre-miR-16-1 microRNA duplex to overcome anti-angiogenic therapy resistance in non-small cell lung cancer

Article Title: Harnessing the cooperative function of duplex from pre-miR-16 hairpin to simultaneously inhibit VEGF and hypoxia pathways in human non-small cell lung cancer

Article References: Wang, Y., Xue, W., Malakhov, P. A., Smirnova, A. V., Pustovalova, M., Kuzmin, D. V., & Leonov, S. (2026). Harnessing the cooperative function of duplex from pre-miR-16 hairpin to simultaneously inhibit VEGF and hypoxia pathways in human non-small cell lung cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03392-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03392-5

Keywords: non-small cell lung cancer, anti-angiogenic therapy, bevacizumab, VEGFA, HIF1A, hypoxia, CD105, Endoglin, miR-16, microRNA duplex, epithelial-mesenchymal transition, chemoresistance

The trial, known as FAB-HCC, enrolled twelve patients with advanced hepatocellular carcinoma who had progressed while receiving atezolizumab plus bevacizumab. The rationale rested on a growing body of evidence that the gut microbiome can act as a rheostat for the immune system, shaping how effectively checkpoint inhibitors unleash T cells against tumors. In cancers such as melanoma, earlier studies had shown that transferring fecal material from patients who responded to immunotherapy into those who did not could sometimes rekindle the anti-tumor response. The Vienna team extended this concept in two directions: they tested the approach in liver cancer, a tumor type arising in an organ intimately connected to the gut through the portal circulation, and they compared donors of two kinds, a patient with hepatocellular carcinoma who had responded robustly to anti-PD-1 therapy and a healthy individual.

Each participant received a single fecal microbiota transplantation via colonoscopy, followed by continued treatment with atezolizumab and bevacizumab. The primary endpoint of the study was safety, measured by the incidence and severity of treatment-related adverse events. This was a critical question, because both fecal transplants and the drug combination carry theoretical risks, particularly in patients with cirrhotic livers whose immune function is already compromised. The results were reassuring. The most frequent grade 3 or 4 treatment-related adverse events were arterial hypertension, seen in five patients, and proteinuria, seen in three, both of which are well-known toxicities of bevacizumab rather than consequences of the transplant. A single case of grade 3 diarrhea was attributed to the fecal microbiota transplantation itself. Importantly, no serious treatment-related adverse events were observed, and the procedure proved feasible in this vulnerable population.

The efficacy signals, while generated in a very small cohort, were eye-catching. Four of the twelve patients, an objective response rate of 33 percent, experienced radiologically confirmed tumor shrinkage after their disease had stopped responding to the same drug combination. The median progression-free survival was 6.9 months, with a 95 percent confidence interval spanning 3.0 to 10.8 months. For a population in which rechallenge with the same regimen would ordinarily be expected to yield little benefit, these numbers suggest that modulating the gut ecosystem may genuinely change the biological terrain on which immunotherapy operates. The authors are careful to frame the trial as hypothesis-generating, and with twelve participants, chance and selection effects cannot be excluded. Still, the consistency between the clinical outcomes and the molecular findings lends the results biological plausibility.

That plausibility comes from an unusually deep set of translational analyses. By sequencing microbial DNA from stool samples collected before and after the transplant, the researchers tracked whether the donor’s microbial community took up residence in the recipient, a phenomenon known as engraftment. After the procedure, the composition of the recipients’ gut microbiomes shifted toward that of their respective donors, indicating that a single colonoscopic delivery can durably alter the intestinal ecosystem. Notably, transplants from the healthy donor appeared to engraft more successfully than those from the responding patient, an observation with practical implications for how donor material might be selected in future trials. The team also documented a meaningful ecological shift in function: bacteria previously associated with immunotherapy response became enriched after the transplant, while deleterious species waned.

The immune consequences of this microbial remodeling were visible in the blood. Following the combined intervention, the number of circulating PD-1-positive CD8-positive T cells, a population often expanded in settings of chronic antigen stimulation and immune exhaustion, decreased. At the same time, a specific subset of monocytes, characterized by the marker CD32b and high expression of CD14 with low CD16, increased. Monocytes and their derivatives are increasingly recognized as key orchestrators of the tumor microenvironment, capable of either supporting or suppressing T-cell activity, and shifts in these populations may reflect a rebalancing of innate immunity toward a more inflammation-competent state. These cellular changes provide a mechanistic bridge between the microbial intervention and the clinical responses observed on imaging.

Perhaps the most novel analytical contribution came from an antibody-sequencing approach known as phage-display immunoprecipitation sequencing, which profiles the repertoire of antibodies circulating in a patient’s blood by measuring their binding to hundreds of thousands of synthetic peptide displays. Rather than finding that overall antibody diversity or composition predicted outcome, the researchers discovered that the stability of the antibody repertoire over time was what changed following the intervention. This suggests that the humoral immune system, the arm responsible for antibody production, undergoes a measurable recalibration when the gut ecosystem is reset and checkpoint blockade is resumed. It is a reminder that cancer immunotherapy responses are systemic events, rippling far beyond the tumor itself, and that tools capable of reading these ripples may eventually help identify which patients are responding long before scans can.

The study also carries a poignant human dimension. The responding patient who served as one of the donors represents a rare example of a cancer patient directly contributing biological material that may benefit others with the same disease. The trial was conducted at a single center with support from Roche, which supplied the investigational medicinal product, and it was registered under ClinicalTrials.gov identifier NCT05750030. The authors acknowledge with gratitude the contributions of patients, donors, and their families, as well as a statistician who contributed to the trial’s design and passed away before its completion, a quiet reminder of the human effort underlying every clinical dataset.

What happens next will determine whether this approach moves from promising pilot to standard of care. The central limitation is unmistakable: twelve patients, no control group, and an open-label design in which neither patients nor physicians were blinded to the intervention. Spontaneous fluctuations in hepatocellular carcinoma, and the possibility that simply continuing atezolizumab and bevacizumab after a treatment holiday benefits some patients, cannot be ruled out. Larger, adequately powered, ideally randomized trials will be needed to confirm that fecal microbiota transplantation genuinely reverses resistance rather than merely coinciding with it. If those trials succeed, the implications would extend well beyond liver cancer. The gut microbiome is already implicated in responses to checkpoint inhibitors across melanoma, lung cancer, and renal cell carcinoma, and a safe, single-procedure intervention that reprograms it could become a universal sensitizing strategy. For now, the Vienna results offer something oncology rarely enjoys after a treatment fails: a scientifically grounded reason to try again, delivered not with a new molecule but with the microscopic residents of a healthier gut.

Subject of Research: Fecal microbiota transplantation combined with atezolizumab-bevacizumab rechallenge in immunotherapy-refractory hepatocellular carcinoma

Article Title: FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study

Article References: Pomej, K., Frick, A., Scheiner, B., Baumgartner, M., Schmetterer, K. G., Reyna-Blanco, C. S., Balcar, L., Pajancic, L., Kreuter, A., Séneca, J., Hausmann, B., Köcher, T., Prinzensteiner, M., Lampichler, K., Rohr-Udilova, N., Chakrabarty, A., Klotz, A., Lampl, A. C., Zinober, K., … Pinter, M. (2026). FMT combined with atezolizumab-bevacizumab in hepatocellular carcinoma refractory to immunotherapy: an open label, single-arm, phase II pilot study. Nature Communications. https://doi.org/10.1038/s41467-026-78219-z

Image Credits: AI Generated

DOI: 10.1038/s41467-026-78219-z

Keywords: fecal microbiota transplantation, hepatocellular carcinoma, atezolizumab, bevacizumab, immunotherapy resistance, gut microbiome, checkpoint inhibitors, phase II pilot study, microbiome engraftment, PD-1, tumor immunology, Nature Communications

The study, published in Holistic Integrative Oncology, compared two maintenance strategies in patients with primary high-grade serous ovarian carcinoma who had responded to first-line platinum-based chemotherapy. One group received Olaparib alone, a PARP inhibitor taken orally twice daily, while the other received Olaparib combined with Bevacizumab, a monoclonal antibody that blocks vascular endothelial growth factor and is delivered intravenously every three weeks. The researchers followed 214 eligible patients drawn from an initial pool of 878 ovarian carcinoma diagnoses, dividing them into a monotherapy group of 139 patients and a combination group of 75, treated between July 2018 and April 2025.

The biological logic behind combining these two agents is elegant. PARP inhibitors such as Olaparib exploit a vulnerability known as synthetic lethality: many high-grade serous ovarian tumors carry defects in homologous recombination, the molecular machinery that repairs dangerous DNA breaks, often because of mutations in the BRCA1 or BRCA2 genes. When PARP-mediated repair is also blocked, cancer cells accumulate lethal DNA damage and die. Bevacizumab attacks from an entirely different angle, starving tumors of their blood supply by neutralizing VEGF signaling. Preclinical work has long suggested these pathways are complementary, because VEGF-driven angiogenesis and PARP-mediated DNA repair both sustain tumor survival, and blocking them together may produce effects neither drug achieves alone.

That synergy was validated in the landmark PAOLA-1 trial, which showed that Olaparib plus Bevacizumab as first-line maintenance extended progression-free survival compared with Bevacizumab alone, particularly in patients whose tumors were homologous recombination deficient. The combination subsequently entered major clinical guidelines, including those of the National Comprehensive Cancer Network. But randomized trials enroll carefully selected patients under idealized conditions, and oncologists have lacked robust real-world evidence on how the two strategies compare head to head in routine practice, where patients carry comorbidities, varied performance statuses, and socioeconomic realities that trials often exclude. The new study was designed to fill exactly that gap.

The headline result is, on the surface, a null finding. Across the entire cohort of 214 patients, Kaplan-Meier analysis revealed no statistically significant difference in progression-free survival between the two regimens, with a log-rank P value of 0.82. Median progression-free survival was 20.3 months for patients on Olaparib alone and 20.4 months for those on the combination, a difference of barely three weeks. Overall survival likewise showed no significant separation between the groups, with a log-rank P value of 0.40. For an unselected population of women with high-grade serous ovarian carcinoma, adding Bevacizumab to Olaparib maintenance did not appear to delay progression or extend life.

But the story changed dramatically when the researchers stratified patients by molecular biomarker. Among the subgroup with documented BRCA mutations, progression-free survival remained comparable between the two treatments, with a log-rank P value of 0.79. Overall survival, however, told a different story: patients receiving the Olaparib-Bevacizumab combination experienced a statistically significant improvement in overall survival compared with those on monotherapy, with a log-rank P value of 0.01. In a disease where the median overall survival has historically hovered in the range of a few years, a survival advantage confined to a biomarker-defined subgroup is precisely the kind of signal that reshapes treatment algorithms.

The mechanistic explanation for this divergence is intriguing. Because progression-free survival was similar in the BRCA-mutated subgroup, the survival benefit cannot simply reflect delayed initial progression. Instead, the authors suggest that the combination may alter the natural history of the disease after progression, perhaps producing more durable clinical control or enhancing the effectiveness of subsequent lines of therapy. One plausible mechanism involves vascular normalization: by pruning the chaotic, leaky vasculature that tumors build, Bevacizumab may temporarily normalize blood flow within the tumor, improving drug delivery and reducing hypoxia, a well-known driver of resistance to PARP inhibition. In BRCA-mutated tumors, which are already exquisitely sensitive to PARP blockade, this vascular effect may amplify the DNA-damaging pressure on cancer cells in ways that translate into longer life.

The safety data provide reassurance that this added benefit does not come at the cost of added toxicity, at least for the toxicities examined. The researchers focused on clinically relevant adverse events, including hematologic toxicities such as anemia, neutropenia, and thrombocytopenia, as well as hepatotoxicity and nephrotoxicity. The incidence rates of these events were similar between the two treatment groups, with no statistically significant differences observed. Median duration of maintenance therapy was 7.05 months in the monotherapy group and 9.73 months in the combination group, suggesting that patients tolerated the dual regimen well enough to remain on treatment for longer periods.

The study also probed whether other molecular features might predict differential benefit, examining patients with TP53 mutations as determined by immunohistochemistry on primary surgical specimens. In that subgroup, neither progression-free survival nor overall survival differed significantly between the two regimens, with log-rank P values of 0.25 and 0.76 respectively. A multivariate Cox proportional hazards analysis incorporating age, FIGO stage, residual disease status, and key immunohistochemical markers found no factor independently associated with overall survival, underscoring how difficult prognostication remains in this heterogeneous disease and how much the field still depends on biomarker-driven subgroup analysis.

The authors are candid about the limitations of their work. As a single-institution retrospective cohort study, it is vulnerable to selection bias and unmeasured confounding, and the modest sample size, particularly within the BRCA-mutated subgroup, limits statistical power. Certain baseline characteristics, such as age, were not fully balanced between the treatment groups, and given that BRCA status is itself a strong predictor of PARP inhibitor response, residual confounding cannot be excluded even with multivariate adjustment. These caveats mean the survival signal should be treated as hypothesis-generating rather than definitive, and the researchers call for prospective studies with larger, well-annotated cohorts and comprehensive biomarker profiling to validate the finding.

Even with those caveats, the clinical message is clear and potentially practice-changing. For women with high-grade serous ovarian carcinoma who lack BRCA mutations, Olaparib monotherapy appears to deliver equivalent benefit as first-line maintenance, sparing patients the inconvenience, cost, and infusion schedule of added Bevacizumab without sacrificing survival. For the clinically critical subset harboring BRCA mutations, however, the combination regimen is associated with a significant overall survival advantage, reinforcing and extending the evidence from PAOLA-1 and supporting the continued use of biomarker stratification when selecting maintenance therapy. In an era where precision oncology increasingly determines who benefits from which drug, this study is a textbook example of why the question is no longer simply whether a treatment works, but for whom.

Subject of Research: Comparison of Olaparib monotherapy versus Olaparib plus Bevacizumab as first-line maintenance therapy in primary high-grade serous ovarian carcinoma

Article Title: Comparison of survival outcomes of Olaparib or Olaparib combine with Bevacizumab in patients with primary high-grade serous ovarian carcinoma

Article References: Cai, L., Fang, H., Zhang, X., Wang, Z., Wang, J., Fang, C., & Wu, N.-Y. Y. (2026). Comparison of survival outcomes of Olaparib or Olaparib combine with Bevacizumab in patients with primary high-grade serous ovarian carcinoma. Holistic Integrative Oncology, 5(1), Article 23. https://doi.org/10.1007/s44178-026-00232-5

Image Credits: AI Generated

DOI: 10.1007/s44178-026-00232-5

Keywords: ovarian cancer, high-grade serous ovarian carcinoma, Olaparib, Bevacizumab, PARP inhibitor, BRCA mutation, maintenance therapy, overall survival, progression-free survival, biomarker-driven therapy, anti-angiogenic therapy, real-world evidence